You’re invited to a panel discussion with leading gene therapy developers!

Adeno-associated viruses (AAV) have become an essential tool in the development of viral vector-based gene therapies. However, as researchers continue to push the boundaries of what AAVs can do, they are encountering new challenges in producing sufficient quantities of AAVs for gene therapy products and getting delivery vehicles and their genetic payloads across the blood-brain barrier.

To help shed light on these challenges, we are excited to invite you to view a recorded panel discussion on the topic. During the discussion, Bernardo Cordovez, founder and chief science officer of Halo Labs, Nicole Faust, general manager of cell line development at Cytiva's Cevec, Jacinthe Gingras, head of the discovery biology unit at Homology Medicines, and Stephen Wellman, director of content and strategy at Science and Medicine Group, delve into these challenges and discuss potential solutions.